Doximity Inc. reported fiscal first-quarter 2026 results that exceeded Wall Street expectations and lifted its full-year outlook, sending the telehealth platform’s shares up as much as 11% in late trading. Revenue rose 15% from a year earlier to $145.9 million, topping the $139 million consensus, while diluted non-GAAP earnings per share reached $0.36 versus analysts’ $0.31 estimate. Net income climbed to $53.3 million, and adjusted EBITDA increased 21% to $79.8 million, yielding a 54.7% margin. Chief Executive Officer Jeff Tangney said the quarter delivered “record engagement across our newsfeed, workflow, and AI products.” Usage of the company’s artificial-intelligence tools expanded fivefold year-over-year, with more than 630,000 prescribers employing its digital workflow services. During the period, Doximity rolled out the AI Scribe documentation tool and completed the purchase of Pathway Medical, moves the company said will deepen its clinical content and automation offerings. Looking ahead, the San Francisco-based firm projected second-quarter revenue of $157 million to $158 million and adjusted EBITDA of $87 million to $88 million. For the full fiscal year ending March 2026, Doximity now targets revenue of $628 million to $636 million, up from prior guidance, along with adjusted EBITDA of $341 million to $349 million. The improved forecast underscores management confidence that continued adoption of its AI-powered services will sustain double-digit growth despite a cautious healthcare advertising environment.